{
    "items": [
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/ai-powered-cancer-immunotherapy-discovery-could-be-a-step-closer\" title=\"AI-powered cancer immunotherapy discovery could be a step closer\" class=\"state-published\">AI-powered cancer immunotherapy discovery could be a step closer</a>\n            </h4>\n            \n            \n                \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/search?category=tenant-news\" title=\"Tenant news\">\n\t\t                <span class=\"label label-primary\">Tenant news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n            \n\n            \n                <p class=\"details\" itemprop=\"datePublished\">28 November 2024</p>\n            \n                            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">TechBio startup, Exogene, is leveraging artificial intelligence (AI) to develop innovative immunotherapies with the potential to eliminate untreatable solid tumours in cancer patients. Through a collaboration with German company Alithea Bio, Exogene hopes to speed up cancer immunotherapy discovery and make it more cost-effective.</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/theolytics-doses-first-patient-in-phase-i-iia-trial-of-theo-260-in-ovarian-cancer\" title=\"Theolytics doses first patient in Phase I/IIa Trial of THEO-260 in ovarian cancer\" class=\"state-published\">Theolytics doses first patient in Phase I/IIa Trial of THEO-260 in ovarian cancer</a>\n            </h4>\n            \n            \n                \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/search?category=alumni-news\" title=\"Alumni news\">\n\t\t                <span class=\"label label-primary\">Alumni news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n            \n\n            \n                <p class=\"details\" itemprop=\"datePublished\">19 November 2024</p>\n            \n                            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">Theolytics, a clinical-stage biotechnology company developing next-generation oncolytic immunotherapies, has dosed the first patient in its Phase I/IIa multi-centre, open-label first-in-human trial (OCTOPOD - NCT06618235) of THEO-260 in patients with advanced-stage platinum-resistant ovarian cancer (PROC).</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/omass-therapeutics-appoints-professor-steven-charlton-as-chief-scientific-officer\" title=\"OMass Therapeutics appoints Professor Steven Charlton as Chief Scientific Officer\" class=\"state-published\">OMass Therapeutics appoints Professor Steven Charlton as Chief Scientific Officer</a>\n            </h4>\n            \n            \n                \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/search?category=alumni-news\" title=\"Alumni news\">\n\t\t                <span class=\"label label-primary\">Alumni news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n            \n\n            \n                <p class=\"details\" itemprop=\"datePublished\">15 November 2024</p>\n            \n                            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">OMass Therapeutics (\u2018OMass\u2019 or \u2018the Company\u2019), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces the appointment of Professor Steven Charlton as Chief Scientific Officer (CSO), effective 1 December 2024. He will take on the role from Dr Ali Jazayeri, who is leaving OMass to pursue other opportunities.</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/exogene-could-be-a-step-closer-to-ai-powered-immunotherapy-discovery\" title=\"Exogene could be a step closer to AI-powered immunotherapy discovery\" class=\"state-published\">Exogene could be a step closer to AI-powered immunotherapy discovery</a>\n            </h4>\n            \n            \n                \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/search?category=tenant-news\" title=\"Tenant news\">\n\t\t                <span class=\"label label-primary\">Tenant news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n            \n\n            \n                <p class=\"details\" itemprop=\"datePublished\">11 November 2024</p>\n            \n                            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">Through UK-Germany Collaborative R&amp;D funding, Exogene is collaborating with the German company Alithea Bio, aiming to accelerate cancer immunotherapy discovery and make it more cost-effective.</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/cyanocapture-at-the-forefront-h2boost-deployment-and-cosec-horizon-grant-to-scale-biogenic-co2-capture\" title=\"CyanoCapture at the forefront: H2Boost deployment and COSEC Horizon grant to scale biogenic CO2 capture\" class=\"state-published\">CyanoCapture at the forefront: H2Boost deployment and COSEC Horizon grant to scale biogenic CO2 capture</a>\n            </h4>\n            \n            \n                \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/search?category=alumni-news\" title=\"Alumni news\">\n\t\t                <span class=\"label label-primary\">Alumni news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n            \n\n            \n                <p class=\"details\" itemprop=\"datePublished\">10 November 2024</p>\n            \n                            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">CyanoCapture is making significant strides in advancing sustainable carbon capture technologies with its involvement in two major projects. Both initiatives highlight CyanoCapture's commitment to pioneering carbon-negative solutions and driving progress toward a sustainable, low-carbon future.</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/infinitopes-to-showcase-breakthroughs-on-cancer-vaccine-development-at-sitc-2024-insight-into-a-double-blind-phase-i-iia-clinical-trial\" title=\"Infinitopes to showcase breakthroughs on cancer vaccine development at SITC 2024: Insight into a double-blind, Phase I/IIa clinical trial\" class=\"state-published\">Infinitopes to showcase breakthroughs on cancer vaccine development at SITC 2024: Insight into a double-blind, Phase I/IIa clinical trial</a>\n            </h4>\n            \n            \n                \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/search?category=tenant-news\" title=\"Tenant news\">\n\t\t                <span class=\"label label-primary\">Tenant news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n            \n\n            \n                <p class=\"details\" itemprop=\"datePublished\">8 November 2024</p>\n            \n                            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">Infinitopes, an integrated cancer biotech combining world leading platforms in precision antigen discovery with vaccine vectors capable of durably stimulating protective immune responses, today announces that it will be presenting three posters on its pioneering cancer vaccine discovery and development, including one that has been recognised as a \u2018top 100\u2019 poster presentation, at the Society for Immunotherapy of Cancer (SITC) 2024, held in Houston, US, from 6-10th November.</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/leading-academics-and-innovators-join-refreshed-bioescalator-management-board\" title=\"Leading academics and innovators join refreshed BioEscalator Management Board\" class=\"state-published\">Leading academics and innovators join refreshed BioEscalator Management Board</a>\n            </h4>\n            \n            \n                \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/search?category=bioescalator-news\" title=\"BioEscalator news\">\n\t\t                <span class=\"label label-primary\">BioEscalator news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n            \n\n            \n                <p class=\"details\" itemprop=\"datePublished\">30 October 2024</p>\n            \n                            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">In its first major refresh since its establishment in 2018, the BioEscalator is delighted to welcome five leading University of Oxford academics and innovators to its Management Board. Professors Catherine Green OBE, Beth Psaila, Molly Stevens DBE, Krina Zondervan and Peter Callow, Financial Controller of the Medical Sciences Division at the University of Oxford. The Management Board provides a source of expertise for BioEscalator tenants and works to enhance research at the University by building strong links with small life sciences companies.</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/nucleome-therapeutics-announces-a-strategic-collaboration-with-johnson-johnson-to-map-genetic-associations-linked-to-autoimmune-disease\" title=\"Nucleome Therapeutics announces a strategic collaboration with Johnson &amp; Johnson to map genetic associations linked to autoimmune disease\" class=\"state-published\">Nucleome Therapeutics announces a strategic collaboration with Johnson &amp; Johnson to map genetic associations linked to autoimmune disease</a>\n            </h4>\n            \n            \n                \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/search?category=alumni-news\" title=\"Alumni news\">\n\t\t                <span class=\"label label-primary\">Alumni news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n            \n\n            \n                <p class=\"details\" itemprop=\"datePublished\">21 October 2024</p>\n            \n                            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">Nucleome Therapeutics (\u2018Nucleome\u2019 or \u2018the Company\u2019), a biotechnology company using 3D genomics to discover precision medicines for complex diseases, announces today it has entered a research collaboration with Johnson &amp; Johnson*.</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/internationally-renowned-academic-lee-sweetlove-joins-moa\" title=\"Internationally renowned academic Lee Sweetlove joins Moa\" class=\"state-published\">Internationally renowned academic Lee Sweetlove joins Moa</a>\n            </h4>\n            \n            \n                \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/search?category=alumni-news\" title=\"Alumni news\">\n\t\t                <span class=\"label label-primary\">Alumni news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n            \n\n            \n                <p class=\"details\" itemprop=\"datePublished\">15 October 2024</p>\n            \n                            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">Moa Technology is pleased to announce that Lee Sweetlove, Professor of Plant Sciences at the University of Oxford, has joined our team. Professor Sweetlove will be working to further understanding of the novel herbicidal modes of action discovered by Moa, which we are currently developing into safe, effective and affordable solutions to protect harvests from crop-killing weeds.</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/moa2019s-ground-breaking-science-features-in-journal-weed-science\" title=\"Moa\u2019s groundbreaking science features in journal Weed Science\" class=\"state-published\">Moa\u2019s groundbreaking science features in journal Weed Science</a>\n            </h4>\n            \n            \n                \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/search?category=alumni-news\" title=\"Alumni news\">\n\t\t                <span class=\"label label-primary\">Alumni news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n            \n\n            \n                <p class=\"details\" itemprop=\"datePublished\">9 October 2024</p>\n            \n                            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">Breaking the 30 year impasse in novel herbicide discovery.</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/a-plant-sciences-spin-out-flourishes-at-the-bioescalator\" title=\"A plant sciences spin-out flourishes at the BioEscalator\" class=\"state-published\">A plant sciences spin-out flourishes at the BioEscalator</a>\n            </h4>\n            \n            \n                \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/search?category=company-insights\" title=\"Company insights\">\n\t\t                <span class=\"label label-primary\">Company insights</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n            \n\n            \n                <p class=\"details\" itemprop=\"datePublished\">2 October 2024</p>\n            \n                            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">\u2018Mighty oaks from little acorns grow.\u2019 And so it is with novel herbicide developer Moa Technology, which has grown from four people when it first became a BioEscalator tenant to a company of 85 with research facilities in Oxford and Yorkshire.</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/enara-bio-raises-32-5-million-series-b-financing-to-advance-first-in-class-pipeline-of-tcr-based-immunotherapies-targeting-novel-dark-antigens\" title=\"Enara Bio raises $32.5M Series B financing to advance first-in-class pipeline of TCR-based immunotherapies targeting novel Dark Antigens\u00ae\" class=\"state-published\">Enara Bio raises $32.5M Series B financing to advance first-in-class pipeline of TCR-based immunotherapies targeting novel Dark Antigens\u00ae</a>\n            </h4>\n            \n            \n                \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/search?category=alumni-news\" title=\"Alumni news\">\n\t\t                <span class=\"label label-primary\">Alumni news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n            \n\n            \n                <p class=\"details\" itemprop=\"datePublished\">2 October 2024</p>\n            \n                            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">Enara Bio today announces the closing of a $32.5M Series B financing supported by a strong syndicate of new and existing biotech investors. The round was co-led by new investors, Pfizer Ventures and M Ventures, with participation from all existing investors, including RA Capital, Samsara BioCapital and SV Health Investors.</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/omass-therapeutics-expands-development-team-with-key-appointments-in-us-and-uk-and-announces-the-nomination-of-clinical-candidate-against-mc2\" title=\"OMass Therapeutics expands development team with key appointments in US and UK and announces the nomination of clinical candidate against MC2\" class=\"state-published\">OMass Therapeutics expands development team with key appointments in US and UK and announces the nomination of clinical candidate against MC2</a>\n            </h4>\n            \n            \n                \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/search?category=alumni-news\" title=\"Alumni news\">\n\t\t                <span class=\"label label-primary\">Alumni news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n            \n\n            \n                <p class=\"details\" itemprop=\"datePublished\">30 September 2024</p>\n            \n                            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">OMass Therapeutics (\u2018OMass\u2019 or \u2018the Company\u2019), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces the candidate nomination of its lead program targeting the melanocortin-2 (MC2) receptor and key appointments to support its progress towards becoming a clinical-stage company.</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/moa-and-biomar-announce-bio-herbicide-collaboration\" title=\"Moa and Biomar announce bio-herbicide collaboration\" class=\"state-published\">Moa and Biomar announce bio-herbicide collaboration</a>\n            </h4>\n            \n            \n                \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/search?category=alumni-news\" title=\"Alumni news\">\n\t\t                <span class=\"label label-primary\">Alumni news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n            \n\n            \n                <p class=\"details\" itemprop=\"datePublished\">16 September 2024</p>\n            \n                            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">Moa has boosted its bio-herbicide research and development programme with a new long-term collaboration agreement with Biomar Microbial Technologies.</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/alchemab-appoints-co-founder-jane-osbourn-as-chief-executive-officer\" title=\"Alchemab appoints Co-Founder Jane Osbourn as Chief Executive Officer\" class=\"state-published\">Alchemab appoints Co-Founder Jane Osbourn as Chief Executive Officer</a>\n            </h4>\n            \n            \n                \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/search?category=alumni-news\" title=\"Alumni news\">\n\t\t                <span class=\"label label-primary\">Alumni news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n            \n\n            \n                <p class=\"details\" itemprop=\"datePublished\">11 September 2024</p>\n            \n                            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">Alchemab Therapeutics (Alchemab), a pharmaceutical company aiming to identify and develop naturally occurring therapeutic antibodies from resilient individuals, today announces that Jane Osbourn, OBE, FMEDSCI, PhD, Alchemab\u2019s Chief Scientific Officer (CSO), has succeeded Young Kwon, PhD as Chief Executive Officer (CEO) and member of the Board.</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/cardiatec-secures-6-5m-seed-funding-to-advance-its-multi-omics-drug-discovery-platform-for-cardiovascular-diseases\" title=\"CardiaTec secures $6.5M seed funding to advance its multi-omics drug discovery platform for cardiovascular diseases\" class=\"state-published\">CardiaTec secures $6.5M seed funding to advance its multi-omics drug discovery platform for cardiovascular diseases</a>\n            </h4>\n            \n            \n                \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/search?category=alumni-news\" title=\"Alumni news\">\n\t\t                <span class=\"label label-primary\">Alumni news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n            \n\n            \n                <p class=\"details\" itemprop=\"datePublished\">9 September 2024</p>\n            \n                            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">CardiaTec, a TechBio company employing computational methods to decode the biology behind cardiovascular disease, has secured $6.5M in seed funding led by Montage Ventures with participation from Laidlaw Scholars Ventures, Apex Ventures, and Continuum Health Ventures.</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/eterna-biologics-revolutionising-rna-therapeutics\" title=\"Eterna Biologics: Revolutionising RNA therapeutics\" class=\"state-published\">Eterna Biologics: Revolutionising RNA therapeutics</a>\n            </h4>\n            \n            \n                \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/search?category=bioescalator-news\" title=\"BioEscalator news\">\n\t\t                <span class=\"label label-primary\">BioEscalator news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/search?category=tenant-news\" title=\"Tenant news\">\n\t\t                <span class=\"label label-primary\">Tenant news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n            \n\n            \n                <p class=\"details\" itemprop=\"datePublished\">28 August 2024</p>\n            \n                            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">We are excited to welcome Eterna Biologics, a University of Oxford biotech spinout company with a mission to unleash the full potential of RNA medicines. The company aims to enhance global health by expanding the applicability of RNA-targeting medicine to develop treatment for a wide range of human conditions.</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/evolvere-biosciences-accepted-into-the-prestigious-y-combinator-program\" title=\"Evolvere Biosciences accepted into the prestigious Y Combinator program\" class=\"state-published\">Evolvere Biosciences accepted into the prestigious Y Combinator program</a>\n            </h4>\n            \n            \n                \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/search?category=tenant-news\" title=\"Tenant news\">\n\t\t                <span class=\"label label-primary\">Tenant news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n            \n\n            \n                <p class=\"details\" itemprop=\"datePublished\">23 August 2024</p>\n            \n                            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">The team of University of Oxford students is making strides that could transform our approach to antibiotics.</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/u-ploid-thrilled-to-join-the-bioescalator-community\" title=\"U-Ploid thrilled to join the BioEscalator Community\" class=\"state-published\">U-Ploid thrilled to join the BioEscalator Community</a>\n            </h4>\n            \n            \n                \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/search?category=bioescalator-news\" title=\"BioEscalator news\">\n\t\t                <span class=\"label label-primary\">BioEscalator news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/search?category=tenant-news\" title=\"Tenant news\">\n\t\t                <span class=\"label label-primary\">Tenant news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n            \n\n            \n                <p class=\"details\" itemprop=\"datePublished\">21 August 2024</p>\n            \n                            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">U-Ploid Biotechnologies joins the BioEscalator to develop groundbreaking therapeutics that improve egg quality and revolutionise IVF.</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/moa-announces-international-field-trial-success-at-the-acs-autumn-conference-in-denver\" title=\"Moa announces international field trial success at the ACS autumn conference in Denver\" class=\"state-published\">Moa announces international field trial success at the ACS autumn conference in Denver</a>\n            </h4>\n            \n            \n                \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/search?category=alumni-news\" title=\"Alumni news\">\n\t\t                <span class=\"label label-primary\">Alumni news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n            \n\n            \n                <p class=\"details\" itemprop=\"datePublished\">19 August 2024</p>\n            \n                            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">Oxford University spin-out Moa Technology has announced excellent results in multi-country field trials of promising new classes of herbicide with novel modes of action recently discovered by the company.</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n"
    ], 
    "more": "\n\n    \n        <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/pepgen-announced-its-first-participant-dosed-in-a-phase-1-clinical-trial-of-pgn-edo51-for-the-treatment-of-duchenne-muscular-dystrophy/search?32dc5f40-4f32-11f1-821f-e92dc95b75f5=&amp;b_start:int=140&amp;tab=newsitem&amp;format=json&amp;random=5b1ae0ea-e4c0-4d03-908f-f254eaea312c\" title=\"Load more\" class=\"btn btn-default load-more-button\">\n            Load More\n        </a>\n    \n\n", 
    "msg": ""
}